First Time Loading...

Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 12.87 USD -5.44% Market Closed
Updated: May 10, 2024

Y-mAbs Therapeutics Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Y-mAbs Therapeutics Inc
Gross Profit Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Gross Profit
$73.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Gross Profit
$36.1B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$20.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.6B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$8.6B
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$11.3B
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is Y-mAbs Therapeutics Inc's Gross Profit?
Gross Profit
73.5m USD

Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Gross Profit amounts to 73.5m USD.

What is Y-mAbs Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 1Y
27%

Over the last year, the Gross Profit growth was 27%.